Optimization and Validation of Two Miniaturized Glucocerebrosidase Enzyme Assays for High Throughput Screening
Daniel J. Urban, Wei Zheng, Ozlem Goker-Alpan, Ajit Jadhav, Mary E. LaMarca, James Inglese, Ellen Sidransky and Christopher P. Austin
Pages 817-824 (8)
Glucocerebrosidase (GC) catalyzes the hydrolysis of β-glucocerebroside to glucose and ceramide in lysosomes. Mutations in the glucocerebrosidase gene (GBA) result in Gaucher disease, an autosomal recessive lysosomal storage disorder. Many of the mutations encountered in patients with Gaucher disease are missense alterations that may cause misfolding, decreased stability and/or mistrafficking of this lysosomal protein. Some inhibitors of GC have been shown to act as chemical chaperones, stabilizing the conformation of mutant proteins and thus restoring their function. High throughput screening (HTS) of small molecule libraries for such compounds with potential for chaperone therapy requires an accurate, reproducible and sensitive assay method. We have adapted and optimized two fluorogenic GC enzyme assays and miniaturized them into the 1536-well plate format for HTS. The two substrates, 4-methylumbelliferyl β-Dglucopyranoside and resorufin β-D-glucopyranoside, have K values of 768 μM and 33 μM, respectively, and different emission spectra. Paired screening with the two assays helps to eliminate false inference of activity due to autofluorescence or fluorescence quenching by the screened compounds. Test screens with the LOPAC library indicated that both assays were robust for HTS, and gave comparable results for GC inhibitor activities. These two assays can be used to identify both GC activators and inhibitors with potential therapeutic value.
Glucocerebrosidase, beta-glucosidase, Gaucher disease, small molecule, assay optimization, assay miniaturization, HTS, quantitative high throughput screening, qHTS
(WZ) NIH Chemical Genomics Center, National Human Genome Research Institute, NIH, 9800 Medical Center Drive, MSC 3370, Bethesda, MD 20892-3370, USA.